Functional promoter -765 G > C variant in COX-2 gene is associated with the susceptibility of breast cancer in Chinese Han women

Table 4 The associations between the COX-2 -765 G > C polymorphism and clinical characteristics of breast cancer patients

Variables	COX-2 -765 G > C genotypes		P*	OR (95% CI)^†
	GG (N, %)	GC/CC (N, %)
Tumor size
Less than 2 cm	116 (92.1)	10 (7.9)	0.006	1.00 (reference)
More than 2 cm	278 (82.0)	61 (18.0)		3.01 (1.47–6.12)
LN involvement
Negative	206 (82.1)	45 (17.9)	0.084	1.00 (reference)
Positive	188 (87.9)	26 (12.1)		0.63 (0.38–1.07)
ER
Negative	140 (86.4)	22 (13.6)	0.459	1.00 (reference)
Positive	254 (83.8)	49 (16.2)		1.27 (0.62–2.61)
PR
Negative	179 (85.7)	30 (14.3)	0.620	1.00 (reference)
Positive	215 (84.0)	41 (16.0)		0.97 (0.49–1.93)
HER-2
Negative	262 (84.8)	47 (15.2)	0.961	1.00 (reference)
Positive	132 (84.6)	24 (15.4)		1.07 (0.61–1.86)

ER, estrogen receptor; PR, progestin receptor; LN, lymph node; HER-2, human epidermal growth factor receptor 2; CI, confidence interval; OR, odds ratio. The frequency of the variant genotypes of COX-2 -765 G > C polymorphism was significant higher in patients with larger tumor size (>2 cm). *Two-sided χ² test for the distributions of genotype and allele frequencies. ^†Adjusted for tumor size, LN involvement, ER, PR and HER-2 status.